Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1

Wenping Liu1, Bing Huang, Yashu Kuang

  • 1School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China.

Molecular Biosystems
|March 23, 2017
PubMed

Insights

Blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1 is effective for cancer treatment. Molecular dynamics simulations reveal PD-1’s CC’ loop flexibility is key to PD-L1 binding, involving both conformational selection and induced fit.

Area of Science:

  • Immunology
  • Structural Biology
  • Computational Biology

Background:

  • Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and its ligand PD-L1 pathway have shown significant promise in cancer therapy.
  • Structural studies of PD-1 reveal conformational flexibility, particularly in the CC' loop, which transitions between open and closed states.

Purpose of the Study:

  • To investigate the role of the CC' loop's conformational dynamics in the molecular recognition between PD-1 and PD-L1.
  • To elucidate the binding mechanism by comparing apo-PD-1 and the PD-1/PD-L1 complex.

Main Methods:

  • Molecular dynamics simulations were employed to compare the open and closed conformations of the CC' loop in apo-PD-1 and the PD-1/PD-L1 complex.
  • Analysis focused on hydrogen bonding patterns and conformational transitions.

Main Results:

  • The CC' loop in apo-PD-1 can access both open and closed states due to the moderate stability of intramolecular hydrogen bonds (SER71-THR120).
  • PD-L1 binding promotes a rapid switch to the closed conformation and stabilizes it via four new intermolecular hydrogen bonds.
  • This suggests a binding mechanism involving both conformational selection and induced fit.

Conclusions:

  • The conformational flexibility of the PD-1 CC' loop is a critical determinant in its interaction with PD-L1.
  • Understanding this dynamic interplay is crucial for the rational design of novel structure-based drugs targeting the PD-1/PD-L1 axis for cancer immunotherapy.

Related Concept Videos

Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.5K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.4K
Induced-fit Model01:13

Induced-fit Model

Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
90.8K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.0K